Hoth Therapeutics Says the Possibilities Could Be Endless

Photo by Hoth Therapeutics

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

On Sept. 30, Hoth Therapeutics Inc. HOTH CEO Robb Knie presented its clinical and financial updates at the Benzinga Small Cap Conference, highlighting the company’s accomplishments and sharing what is to come. 

Biolexa and HT00-1: Updates and Projections

Hoth recently completed the first cohort in its trial of BioLexa, the company’s antimicrobial topical formulation for the treatment of diseases mediated by Staphylococcal biofilms, with no adverse effects. It is now approved to start screening and enrolling for the 2nd cohort for patients with atopic dermatitis this fall. Phase 1b clinical trials in humans for the treatment of mild to moderate atopic dermatitis (AD) will be available this year.

BioLexa’s value proposition includes a growing market in the AD sector, expected to reach $18.3 billion by the end of 2027. This compound, in the form of a lotion, prevents biofilm formation and allows the antibiotic to more effectively treat the underlying infection. It also addresses an unmet need in the treatment of moderate to mild AD populations. 

Hoth also discussed another drug it is developing, HT-001, a topical formulation for the treatment of patients with skin toxicities resulting from EGFR inhibitor cancer therapies. This would be a first-to-market solution for patients who have developed skin toxicities from EGFR inhibitor therapies as there is nothing on the market to treat the condition. A pre-investigational new drug application (Pre-IND) was also filed recently with the Food and Drug Administration (FDA) to start the study. Hoth stated that the market associated with these epidermal growth factor receptor (EGFR) inhibitors is predicted to grow to more than $391 million by the end of 2030. Future IND-enabling studies are expected this year and a Phase 2a clinical trial in patients is targeted for 2022. 

Updates in Hoth’s Extensive Drug Pipeline Pre-Clinical candidates:

Updates on other drugs in the pipeline include:

HT-ALZ, treatment for Alzheimer’s: proof of concept studies showed it had good effects on plaque buildup in the brain and cognitive/behavioral function. Hoth is currently evaluating that data in preclinical studies and hopes to share it soon.

HT-003 Platform: Hoth is currently completing a proof of concept preclinical studies and safety studies for both acne/psoriasis indications as well as for inflammatory bowel diseases. 

HT-KIT, for cell-derived cancers and anaphylaxis: White papers on the proof of concept studies have already been published. Hoth has already started drug development and formulation and plans to file for orphan drug designation. 

HT-006, treating ventilator-associated pneumonia and hospital-associated pneumonia (VAP/HAP): This drug was licensed by the Walter Reed Army Institute of Research and Hoth is currently performing preclinical studies. 

The Direct Detect Breath Diagnostic Device System is under development as a point-of-care/patient-use device that includes a biosensor and an app intended as an aid in the diagnosis of viral infection. The device is currently under the research stage of development and a platform prototype is expected by Q1 2022.

Hoth Therapeutics says that its product pipeline, when combined, has the potential to address multibillion-dollar market opportunities. Hoth's pre-clinical therapeutic prospects might help the company build a strong intellectual property portfolio and expand into new markets in the future. 
 

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.